Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
COL1A1
REST API REST API
Homo sapiens
COL1A1 is differentially expressed in 364 experiments: 217 organism parts: liver, placenta, ... (215 more);, 276 disease states: normal, glioblastoma, ... (274 more);, 125 cell types 485 cell lines 43 compound treatments and 84 other conditions.
Synonyms OI4
Orthologs ENSCING00000006961 (Ciona intestinalis)   Col1a1 (Mus musculus)   CO1A1_BOVIN (Bos taurus)   col1a1a (Danio rerio)   col1a1b (Danio rerio)   Col1a1 (Rattus norvegicus)   col1a1 (Xenopus laevis)   CO1A1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to hydrogen peroxide, plasma membrane, protein binding, cytoplasm, extracellular space, extracellular matrix structural constituent, visual perception, proteinaceous extracellular matrix, extracellular region, blood coagulation, response to nutrient, identical protein binding, axon guidance, response to cAMP, sensory perception of sound, extracellular matrix, collagen, positive regulation of transcription, DNA-dependent, response to mechanical stimulus, protein transport, positive regulation of epithelial to mesenchymal transition, response to corticosteroid stimulus, cellular response to retinoic acid, cellular response to growth factor stimulus, collagen type I, tooth mineralization, leukocyte migration, collagen fibril organization, endochondral ossification, cellular response to mechanical stimulus, intramembranous ossification, bone trabecula formation, negative regulation of cell-substrate adhesion, positive regulation of canonical Wnt receptor signaling pathway, positive regulation of cell migration, embryonic skeletal system development, osteoblast differentiation, ossification, collagen biosynthetic process, blood vessel development, response to inorganic substance, skin development, response to peptide hormone stimulus, skeletal system development, protein heterotrimerization, platelet-derived growth factor binding, skeletal system morphogenesis, cartilage development involved in endochondral bone morphogenesis, skin morphogenesis, face morphogenesis, platelet activation, protein localization to nucleus, cellular response to amino acid stimulus
InterPro Term VWF_C, Collagen, Fib_collagen_C
Gene-Disease Assocation OSTEOGENESIS IMPERFECTA, TYPE IV, EHLERS-DANLOS SYNDROME, TYPE I, CAFFEY DISEASE, OSTEOPOROSIS, EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT, OSTEOGENESIS IMPERFECTA, TYPE I, OSTEOGENESIS IMPERFECTA, TYPE III, DERMATOFIBROSARCOMA PROTUBERANS; DFSP, OSTEOGENESIS IMPERFECTA, TYPE II
UniProt Accession Q9UMA6, Q6LAN8, D3DTX7, P02452
Search EB-eye ENSG00000108821
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
H2347
2
E-GEOD-4342, E-MTAB-62
A549
2
E-GEOD-6013, E-GEOD-3202
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC38
2
E-MTAB-37, E-MTAB-62
KG1
2
E-MTAB-37, E-GEOD-24147
479 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (54 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
macrophage
2
E-GEOD-22373, E-GEOD-5099
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
whole blood
2
E-MTAB-25, E-GEOD-3026
stromal cell
2
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-MEXP-1327, E-GEOD-10797 ... (5 experiments)
monocyte
1
2
E-GEOD-22373, E-GEOD-5099, E-GEOD-11755
119 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, ... (86 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-4290, E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4412 ... (5 experiments)
prostate carcinoma
5
E-GEOD-96, E-MTAB-62, E-GEOD-3868, E-MEXP-2034, E-GEOD-7307 ... (5 experiments)
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
acute promyelocytic leukemia
1
3
E-GEOD-96, E-MTAB-62, E-GEOD-1729, E-GEOD-995
benign prostatic hyperplasia
1
3
E-GEOD-7307, E-MEXP-1243, E-GEOD-3868, E-MEXP-2034
chronic myelogenous leukemia
1
3
E-GEOD-96, E-MTAB-37, E-MTAB-62, E-GEOD-5550
270 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
placebo
2
E-MEXP-1335, E-MEXP-1327
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
17beta-estradiol
4
1
E-GEOD-2292
37 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
1
E-GEOD-3494
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-20115, ... (18 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (45 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-6532, E-GEOD-4922, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.452 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM